Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:ORIC NASDAQ:SYRE NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.50$2.25$1.60▼$2.77$957.60M1.134.17 million shs1.96 million shsORICOric Pharmaceuticals$10.88+1.0%$10.41$3.90▼$14.67$1.06B1.63766,787 shs1.05 million shsSYRESpyre Therapeutics$17.00+0.1%$16.43$10.91▼$40.26$1.03B2.87418,961 shs339,702 shsVORVor Biopharma$1.96+1.6%$2.09$0.13▼$3.29$248.30M2.057.70 million shs3.06 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%-3.85%+10.13%+26.26%+14.16%ORICOric Pharmaceuticals0.00%+6.35%+12.98%+16.74%+13.45%SYRESpyre Therapeutics0.00%+3.09%+11.55%+0.18%-39.29%VORVor Biopharma0.00%-0.51%-5.31%+775.78%+131.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.50$2.25$1.60▼$2.77$957.60M1.134.17 million shs1.96 million shsORICOric Pharmaceuticals$10.88+1.0%$10.41$3.90▼$14.67$1.06B1.63766,787 shs1.05 million shsSYRESpyre Therapeutics$17.00+0.1%$16.43$10.91▼$40.26$1.03B2.87418,961 shs339,702 shsVORVor Biopharma$1.96+1.6%$2.09$0.13▼$3.29$248.30M2.057.70 million shs3.06 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%-3.85%+10.13%+26.26%+14.16%ORICOric Pharmaceuticals0.00%+6.35%+12.98%+16.74%+13.45%SYRESpyre Therapeutics0.00%+3.09%+11.55%+0.18%-39.29%VORVor Biopharma0.00%-0.51%-5.31%+775.78%+131.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AORICOric Pharmaceuticals 2.89Moderate Buy$17.2958.88% UpsideSYRESpyre Therapeutics 3.29Buy$53.40214.12% UpsideVORVor Biopharma 2.56Moderate Buy$6.07209.52% UpsideCurrent Analyst Ratings BreakdownLatest VOR, SYRE, CRON, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $19.008/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/6/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$65.007/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.006/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$130.28M7.35$0.00 per share5,372.65$2.90 per share0.86ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ASYRESpyre TherapeuticsN/AN/AN/AN/A$7.04 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.0550.0083.33N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)SYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)VORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest VOR, SYRE, CRON, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.6523.53ORICOric PharmaceuticalsN/A16.1316.13SYRESpyre TherapeuticsN/A6.496.49VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%ORICOric Pharmaceuticals95.05%SYRESpyre Therapeutics80.39%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%ORICOric Pharmaceuticals6.82%SYRESpyre Therapeutics15.43%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450383.04 million355.08 millionOptionableORICOric Pharmaceuticals8097.12 million90.50 millionOptionableSYRESpyre Therapeutics7360.40 million51.08 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableVOR, SYRE, CRON, and ORIC HeadlinesRecent News About These CompaniesOMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VOR3 hours ago | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 400,000 SharesSeptember 6 at 8:10 AM | insidertrades.comVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 806,351 SharesSeptember 1, 2025 | americanbankingnews.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives $6.07 Average PT from BrokeragesAugust 27, 2025 | americanbankingnews.comVor Bio to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 19, 2025 | finanznachrichten.deQ3 EPS Estimates for Vor Biopharma Reduced by HC WainwrightAugust 19, 2025 | marketbeat.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2025 | globenewswire.comAnalysts Set Expectations for Vor Biopharma FY2028 EarningsAugust 17, 2025 | marketbeat.comWedbush Brokers Boost Earnings Estimates for Vor BiopharmaAugust 17, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC WainwrightAugust 16, 2025 | marketbeat.comVor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder TreatmentAugust 13, 2025 | marketwatch.comVor says drug licensed from RemeGen succeeded in Sjögren’s studyAugust 13, 2025 | finance.yahoo.comVor Bio Rallies On Strong Data For Autoimmune Drug CandidateAugust 13, 2025 | benzinga.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL InhibitorAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBig Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025Micron Stock Still Cheap Despite 25% Rally, Analysts SayBy Gabriel Osorio-Mazilli | August 19, 2025Shopify’s Risk-Reward Profile Is Suddenly Red HotBy Sam Quirke | August 22, 2025VOR, SYRE, CRON, and ORIC Company DescriptionsCronos Group NASDAQ:CRON$2.50 0.00 (0.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.52 +0.02 (+0.60%) As of 09/5/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Oric Pharmaceuticals NASDAQ:ORIC$10.88 +0.11 (+1.02%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$11.04 +0.16 (+1.46%) As of 09/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Spyre Therapeutics NASDAQ:SYRE$17.00 +0.01 (+0.06%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$16.55 -0.45 (-2.65%) As of 09/5/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Vor Biopharma NYSE:VOR$1.96 +0.03 (+1.55%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.96 0.00 (0.00%) As of 09/5/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
